Bayer announced Q3 revenue of EUR 9.7 billion (USD 10.8 billion) representing 3.1% decline, with 9-month pharmaceutical sales reaching EUR 13.4 billion (USD 14.9 billion), down 0.9% despite strong performance from newer products including Nubeqa (darolutamide) and Kerendia (finerenone). The ophthalmology portfolio showed mixed results with Eylea (aflibercept) 8mg high-dose formulation growing 302% to EUR 551 million (USD 616 million), offsetting competition impact on standard Eylea which declined 2.6% to EUR 2.4 billion (USD 2.7 billion). Nubeqa achieved EUR 1.7 billion (USD 1.9 billion), with 55.8% growth driven by European and US demand for the next-generation AR inhibitor in prostate cancer.

Kerendia for chronic kidney disease (CKD) in type two diabetes (T2D) increased 73.3% to EUR 565 million (USD 632 million), supported by China and US market expansion, while contraceptive Mirena (levonorgestrel) grew 11.3% to EUR 1.0 billion (USD 1.7 billion).

Pipeline advancements include NK1/3 antagonist Lynkuet (elinzetant) receiving first approvals in UK and US for vasomotor symptoms, with European Union and Japan applications under review. Bayer submitted a new indication application for high-dose Eylea in retinal vein occlusion (RVO) with China's National Medical Products Administration (NMPA), and reported clinical programme updates across different therapeutic areas.

PharmCube's NextBiopharm® database shows that Nubeqa has consistently enjoyed double-digit growth since its 2021 launch. Click here to request a free trial for NextBiopharm®.